Abstract Mutant ras oncogenes are associated with various human tumors, being found in approximately 25% of all human cancers. Since its identification, the enzyme Ras protein farnesyltransferase (PFTase), which catalyzes the initial step of Ras-processing, has been viewed as a most promising target for cancer therapy. Consequently, a number of synthetic and natural small molecules have been searched and developed according to this concept during the 1990s. Among these, microbial metabolites have provided diverse structural classes of compounds which exhibit PFTase inhibitory activity. This article reviews our work on PFTase inhibitors originating from microbial metabolites, and the results of similar works carried out by several other research groups.
Introduction
Three ras proto-oncogenes (H, N and K) encode four structurally related 21-kDa membrane-associated guaninenucleotide-binding proteins: H-Ras, N-Ras, K-Ras4A and K-Ras4B [1, 2] , which play a critical role in the control of cellular proliferation and differentiation. The Ras protein is normally localized in the plasma membrane and extensive post-translational processing must occur for this localization and for the biological activity of Ras to be expressed [3, 4] . The first step in this process is the Ras farnesylation by a protein farnesyltransferase (PFTase) [5] . Since activation of Ras protein by a point mutation is found in a variety of human cancer cells, inhibition of PFTase function has been recognized as a critical target for cancer chemotherapy. The first paper on PFTase inhibitors according to such a concept appeared in 1990, in which inhibitory activities of several substrate analog tetrapeptides containing CAAX sequences, consensus C-terminal motif of Ras proteins, were reported [6] .
Our research group has undertaken comprehensive studies on bioactive substances of microbial origin by devising various screening methods. The search for inhibitors of Ras farnesylation started at the beginning of 1990s [7] initially in cooperation with Rhone-Poulenc Rorer S. A., and three groups of novel compounds as well as nine groups of compounds previously isolated with other bioactivities were found via this program. This review summarizes the results obtained from our search for PFTase inhibitors of microbial origin, as well as those found by other research groups.
Although recent studies have revealed that PFTase inhibition is not effective in blocking Ras function, being limited only to H-Ras, the results covered in this review were mostly obtained during the initial search for Ras PFTase inhibitors. The present situation on protein PFTase and other protein prenyltransferases will be discussed later.
Protein Farnesyltransferase (PFTase)
The addition of a farnesyl group to conserved amino acid residues at the carboxy terminus is necessary for the proper functioning of many farnesylated proteins. Ras proteins are GTP/GDP-binding proteins. The GTP-bound conformation is biochemically active and able to transform cells, whereas the GDP-bound state is inactive. The mitogenic activity of normal Ras is modulated by a GDP-GTP cycle. In its GTPbound form, Ras activates several downstream effector pathways that mediate cell proliferation or other effects (Fig. 1) .
The Ras oncoprotein p21 must be localized in the plasma membrane in order to function and transform cells. It, however, lacks the conventional transmembrane or hydrophobic domains typical to membrane-associated proteins. To overcome this, farnesylation of Ras by PFTase occurs as the first step in a series of modifications. It occurs in vivo on a cysteine residue at the conserved C-terminal tetrapeptide sequence present in all Ras protein to form a thioester linkage (CA 1 A 2 X motif [8, 9] , where Cϭ cysteine, A 1 , A 2 ϭaliphatic amino acids, Xϭserine, leucine, methionine, or glutaminic acid). This farnesylation reaction is then followed by cleavage at the third amino acid from the C-terminus to release the A 1 A 2 X sequence, and methylation of resulting carboxy terminal of the cysteine residue (Fig. 2) . Interference with Ras farnesylation would alter membrane localization and transforming activity of ras oncogene, and might lead to the development of useful anticancer drugs. Based on this concept, we have screened extensively for PFTase inhibitors from microbial sources.
Screening and Assay Methods for PFTase Inhibitors used in Our Work
The screening system consisted of two different methods. The first (Method 1) is to use the process of Ras p21 farnesylation by partially purified PFTase directly. The second (Method 2) is to use conjugation between some Saccharomyces cerevisiae haploid cells. In Method 1, PFTase was partially purified from the cytosol of human monocyte THP-1 (ATCC TIB202) [10] , and Ha-ras p21 protein was produced in a bacterial expression system and purified as described previously [11] . The method was For mambrane targeting by K-Ras, polybasic domain at the C-terminus play a role instead of palmitoylation. GDP, guanosine 5Ј-diphosphate; guanosine 5Ј-triphosphate, GAP, GTPase activating protein; GEP, GDP/GTP exchange protein. Cys, cystein; A 1 and A 2 , any aliphatic amino acid; X-COOH, serine, leucine, methionine or glutamic acid.
utilized both for screening of inhibitors and for evaluation of the samples.
Method 2 was based on the consideration that since some of the PFTase inhibitors screened by Method 1 were found to be inactive in vivo, a screening method using yeast cells was devised as an in vivo model [12] . The reproductive cycle of Saccharomyces cerevisiae includes both haploid and diploid phases. In the haploid phase, two cell types, a and a a, each secrets specific mating pheromones, known as a-and a a-factors, respectively. Mating between a-and a a haploid cells result in a third cell type, a/a a diploids [13, 14] . The process and the structures of a-and a a-factors [15] are summarized in Fig. 3 . The a-factor peptide is to be Sfarnesylated at cysteine terminal to function for diploid formation, therefore formation of inhibition zone on the solid culture medium mixed with both haploids, as shown A-a in Fig. 4 , may reflect the inhibition of Cys-farnesylation in vivo. The samples screened according to this method were further confirmed by the method 1.
PFTase Inhibitors Discovered by Our Screening Program
According to our screening methods to find PFTase inhibitors, three groups of novel compounds including pepticinnamins AϳF [16ϳ18], andrastins AϳD [19ϳ22] and kurasoins A, B [23, 24] were newly isolated, and nine groups of known compounds including gliotoxin [25] and acetylgliotoxin [26] , WS5995C [27] , sclerotiorin [28] , thysanone and O-methylthysanone [29] , ab-dehydrocurvularin [30] , granaticins A [31] , B [32] , penisillic acid [33] , spiculisporic acid [34] and citoreohybridones [35] were identified to have PFTase inhibitory activities. Chemical structures of these compounds are shown in Figs. 5 and 6. Their inhibitory activities against PFTase and conjugation between a and a a yeasts are summarized in Table 1 .
Although gliotoxin (GT) and acetylgliotoxin (AGT) isolated from the culture of a fungus strain FO2047 [10] were known compounds, they provided one ot the earliest examples (together with 10'desmethoxystreptonigrin) among the PFTase inhibitors discovered from microbial metabolites. GT and AGT inhibited PFTase with IC 50 3 Fig. 3 Concept of S. cerevisiae mating assay. values of 1.1 m M and 4.4 m M, respectively, whereas the tetrapeptide control CVLS (NH 2 -Cys-Val-Leu-Ser-COOH), a synthetic PFTase inhibitor which mimics the carboxy terminal sequence of Ha-ras-p21 protein, showed IC 50 of 6.6 m M by our assay method. Our experiments suggested GT and AGT act via the corresponding reduced dithiol form, however it was found that neither S-farnesylation nor competition with the CVLS of these substrates occured. Gliotoxin was originally identified as a mycotoxin possessing antimicrobial activity, for which gliotoxin requires the oxidized form (disulfide form). This fact suggests that the mechanism of PFTase inhibition by this compound is distinct from that of antimicrobial activity [7] .
Pepticinnamins AϳF were isolated from Streptomyces sp. OH-4652. Though their chemical structures remained undetermined except for pepticinnamin E, their PFTase inbitory activities were assayed as shown in Table 1 . Among them pepticinnamin C showed most potent inhibition (IC 50 ϳ100 nM), though both cell toxicity and antimicrobial activity of this compound were extremely low. The kinetic analysis indicated that pepticinnamin E inhibits non-competitively with respect to the substrate farnesyl pyrophosphate (Ki, 1.9 m M) and competitively with p21 ras protein (Ki, 1.76 mM) [36] . Andrastins AϳD produced by Penicillium sp. FO-3929 have unique skeletal structure similar to that of citreohybridones reported as antifeedant and insecticidal compounds. Both andrastins and citreohybridones were biosynthesized from a sesquiterpene and a tetraketide units, though they have a common androstane skeleton [21] . Andrastins AϳC and citreohybridones A and B had moderate PFTase inhibitory activities [20] . Among them, citreohybridone B showed most potent inhibition with an IC 50 value of 3.6 mM. When andrastin C was preincubated with PFTase for 20 minutes before the enzyme assay, the inhibition did not change, suggesting that the compound inhibits PFTase reversibly. Kurasoins A and B were isolated from the culture broth of Paecilomyces sp. FO-3684 in the course of our screening for ATPase inhibitors, though their activities were not remarkable. They showed no antimicrobial activity at 50 mg/disk.
Interestingly, manumycin (UCF1-C) and its related compounds were characterized as PFTase inhibitors by a microbial screening using yeast cells [37] , and are structurally closely related to asukamycin (Fig. 7) isolated from the culture of Streptomyces sp. by our group [38, 39] . Both manumycin and asukamycin exhibit antibacterial activities against Gram-positive bacteria. Asukamycin was also found to have anticoccidial activity. Furthermore, frenolicin B [40, 41] , and nanaomycins A and D [42, 43] , formerly isolated in our group from Streptomyces strains as antimycoplasmal and antibacterial compounds, respectively, were recently found to also show PFTase inhibitory activities [44] (for their structures see Fig. 7 ). These three compounds showed inhibitory activities against bovine brain PFTase with IC 50 values of 1.4 m M, 3.2 m M and 1.9 mM, respectively.
PFTase Inhibitors Discovered by Other Groups
As mentioned previously, we initiated the search for the inhibitors of PFTase of microbial origin at the initial stage of work in this field, along with several other groups, as is clearly indicated in the chronological table of PFTase inhibitor discoveries from microbial products ( Table 2 ). The structures of the compounds discovered are shown in Fig. 7 and reported respective PFTase inhibitory activities as well as the producing organisms are listed in Table 3 . Some of the results, including ours, have been discussed in previously published reviews [45, 46] . It should be noted that the values of PFTase inhibitory activities shown in Table 3 are not directly comparable for all cases, because they were obtained by several different methods using different enzyme sources and different acceptor peptides. These are summarized in the Table 3 . In many reports, the biological activities of respective compounds were also discussed in connection with PFTase specificity and other 8 activities such as the effects on geranyl-geranyl transferase, squalene synthase and tumor cells. Literatures cited in Table 3 should be referred to for further information.
Discussion
Mutant ras oncogenes are associated with unregulated cellular growth. Mutation of Ras protein is found to be one of the most common genetic abnormalities, found in approximately 25% of all human cancers. Mutation in KRas is prevalent in some epithelial cancers, including pancreatic cancer (Ͼ90%), colorectal cancer (ϳ50%), and lung cancer (ϳ30%). Mutation in N-Ras occurs in melanoma (10ϳ20%) and some hematologic malignancies. Mutation in H-Ras is rare (15ϳ20%) [1, 2] . This high prevalence made Ras an attractive target for cancer chemotherapy. Several potential strategies for interfering with Ras function have been investigated and the development of a farnsyltransferase inhibitor was initially driven by the desire to inhibit Ras. However, current evidence suggests that the anticancer activity of PFTase inhibitors is not simply due to Ras inhibition [47, 48] . Mammalian cells express three protein prenyltransferases; protein farnesyl-transferase (PFTase), geranylgeranyltransferase-1 (GGTase-1) and geranylgeranyl-transferase-2 (GGTase-2). In addition to Ras, several protein substrates of farnesyltransferase, are critical intermediates of cell signaling and cytoskeletal organization [47, 48] .
Recent studies have clarified that functions of K-Ras4B and N-Ras are not affected by PFTase inhibitors, as they can be alternatively prenylated by geranyl geranylation. Since it is K-ras that is usually mutated in human cancer, PFTase inhibitors were ineffective in binding ras-induced cancer. Current understanding is that the effects of PFTase on human cancer are mediated by inhibition of farnesylated by the inhibition of farnesylated proteins other than Ras such as Rheb, pRL3 and CENP-E, F.
A number of studies have been undertaken to find or create PFTase inhibitors, including synthetic analogs of the CAAX sequence or of farnesyl pyrophosphate (FPP) as well as the natural products with structures resembling neither the CAAX motif nor FPP [45] . As summarized in this review, the PFTase inhibitors of microbial origin reported have amounted to almost 40 compound types and 60 individual substances, and the producing microorganisms range from fungi to actinomycetes of very different taxa. This suggests that, although none of the compounds have yet been practically used in chemotherapy, microorganisms will continue to be attractive potential sources of PFTase inhibitors.
